Founders
Ignaty Leshchiner, PhD
Co-Founder
Associate Professor in Computational Biomedicine at Boston University School of Medicine. Expert in cancer computational biology, genomic technologies, and AI methods for unraveling tumor development, treatment evasion, and metastasis progression.
Dimitri Livitz, PhD
Co-Founder, Head of Data Science
Head of Data Science and Genomics. Formerly at the Broad Institute of Harvard and MIT, co-author of high-profile publications in Nature, Nature Medicine, and Cell. PhD from Columbia University in Bayesian experimental design.
Paul Trukhanov
Co-Founder
Software Architect in Machine Learning at Dana-Farber Cancer Institute. Experienced startup entrepreneur with expertise in biotechnology, healthcare, and data-intensive software engineering, with two successful startup exits.
Elizaveta Leshchiner, PhD
Co-Founder
Focused on experimental and computational cancer biology with strong expertise in technology and high-throughput assay development. PhD from Harvard University; leads a team of scientists at the Broad Institute of Harvard and MIT.
Andrew Jacobs, JD
Co-Founder, CEO
As CEO Andy has a 40-year record of successfully starting, managing and growing multitude of small and medium sized companies, several of which were subsequently sold to public companies. He has served as CEO and a Board Member for companies in the area of computational services and data management for cancer patients, as well as in other fields, and has been heavily involved in several non-profit enterprises, including a foundation providing patient access to experimental cancer vaccines under FDA regulations.
Ultra High Sensitivity Multi-Modal Liquid Biopsy
Ultra Deep Sequencing
Cell-free (cf) DNA sequencing and analysis with unparalleled depth and sensitivity
Unique Epigenetic Data
Comprehensive methylation and nucleosome profiling for deeper biological insights
AI/ML Platform
Proprietary computational platform for advanced analysis and biomarker discovery
An innovative, efficient, and transformative solution for monitoring disease progression and identifying clinically druggable targets.
cfDNA Sequencing
In-depth cfDNA analysis for treatment efficacy assessment, clonal evolution and resistance dynamics for biomarker discovery, revealing signal from all lesions.
Nature Medicine 2019Subclonal Reconstruction
Evolution and resistance analysis of disease reveals latent trends and information invisible from bulk analysis, increasing statistical power in small cohorts.
Nature Medicine 2023Identify Early Drivers
Establish previously unknown early genetic progression of cancers with unobtainable premalignant tissue for early detection, interception and prognostication.
Nature Cancer 2024